Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

@article{Irie1986RegressionOC,
  title={Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.},
  author={ReikoF. Irie and Michael Mickelson},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1986},
  volume={83 22},
  pages={
          8694-8
        }
}
In this study we used human monoclonal antibody (Hu-mAb) L72 as an intratumoral injection of cutaneous metastasis of melanoma to study its anti-tumor effects in human patients. Hu-mAb L72 was developed by transforming peripheral blood lymphocytes from a melanoma patient in vitro with the Epstein-Barr virus, forming a human lymphoblastoid cell line that produces 2-5 micrograms of IgM per ml. This IgM Hu-mAb was shown to react specifically with ganglioside GD2 and have a strong cytotoxic effect… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 68 CITATIONS, ESTIMATED 95% COVERAGE

Intralesional therapy for metastatic melanoma.

  • Expert opinion on pharmacotherapy
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

Immunoglobulin-M purification--challenges and perspectives.

  • Biotechnology advances
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND

Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 1 EXCERPT

FILTER CITATIONS BY YEAR

1987
2017

CITATION STATISTICS

  • 2 Highly Influenced Citations

Similar Papers

Loading similar papers…